Article info
PDFOriginal research
Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer
- Correspondence to Carmen Maria Valencia Soto, Pharmacy, Hospital Universitario Marques de Valdecilla Servicio de Farmacia, 39008 Santander, Cantabria, Spain; carmenmaria.valencia{at}scsalud.es
Citation
Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer
Publication history
- Received August 26, 2021
- Accepted March 24, 2022
- First published April 5, 2022.
Online issue publication
January 18, 2024
Article Versions
- Previous version (27 December 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.